Isotype control apc

Manufactured by BD

Isotype control-APC is a laboratory reagent used in flow cytometry experiments to establish background staining levels. It serves as a negative control, allowing researchers to differentiate specific binding of antibodies from non-specific background signals.

Automatically generated - may contain errors

Lab products found in correlation

Anti human igg apc, by BD (2 mentions) Cd34 apc, by BD (1 mentions) Cd45 percp, by BD (1 mentions) Cd4 fitc, by BD (1 mentions) Cd127 apc, by BioLegend (1 mentions) Cd25 pe, by BioLegend (1 mentions) Hla abc pe, by BioLegend (1 mentions) Hla dr fitc, by BioLegend (1 mentions) Fc500mcl, by Beckman Coulter (1 mentions) Lsrfortessa flow cytometer, by BD (1 mentions) Cytofix buffer, by BD (1 mentions)

Spelling variants of this product

Isotype controls (87 citations) APC mouse IgG2b κ Isotype Control (5 citations) APC mouse IgG1 kappa isotype control antibody (3 citations) APC mouse IgG1 k isotype control (3 citations) Isotypes (2 citations) APC Mouse IgG1 isotype control (2 citations) APC isotype control mouse IgG1κ ( (2 citations)

4 protocols using isotype control apc

Fibrocyte Identification in Peripheral Blood

Check if the same lab product or an alternative is used in the 5 most similar protocols

Peripheral blood fibrocytes were assayed within 24 hours of acquisition from the aforementioned patients and healthy controls. Peripheral blood fibrocytes were delineated according to expression of CD45, CD34 and type- I collagen, as previously described [30 (link), 44 (link)]. The following anti-human fluorochrome-conjugated mouse antibodies were added: CD45- PERCP (catalog #347464), CD34-APC (catalog #560940), isotype control-FITC (catalog #555748), isotype control-PercP (catalog #340762), and isotype control-APC (catalog # 555751) from BD Biosciences (San Jose, CA), Collagen type-I-FITC (catalog #FCMAB412) from Millipore (Temecula, CA).

Chen H., Shan S.J., Mester T., Wei Y.H, & Douglas R.S. (2015). TSH-Mediated TNFα Production in Human Fibrocytes Is Inhibited by Teprotumumab, an IGF-1R Antagonist. PLoS ONE, 10(6), e0130322.

+ Open protocol

+ Expand

Detailed Immune Cell Phenotyping

Check if the same lab product or an alternative is used in the 5 most similar protocols

Cells were stained with the fluorochrome-conjugated monocolonal antibodies against CD4-FITC (BD Biosciences, 555346), CD25-PE (Biolegend, 302606), CD127-APC (Biolegend, 351315), HLA-ABC-PE (Biolegend, 311406), HLA-DR-FITC (Biolegend, 307604), isotype control-FITC (eBioscience, 11-4714), isotype control-PE (eBioscience, 12-4714), and isotype control-APC (BD Biosciences, 550854). After washing with phosphate-buffered saline (PBS), the cells were subsequently detected by flow cytometry using FC500MCL (Beckman Coulter) and data were calculated using FlowJo Software (Tree Star).

Wang B., Lin Y., Hu Y., Shan W., Liu S., Xu Y., Zhang H., Cai S., Yu X., Cai Z, & Huang H. (2017). mTOR inhibition improves the immunomodulatory properties of human bone marrow mesenchymal stem cells by inducing COX-2 and PGE2. Stem Cell Research & Therapy, 8, 292.

+ Open protocol

+ Expand

BHK21 Cell Immunophenotyping Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols

Forty-two hours after transfection, BHK21 cells were harvested, washed with two to four volumes of staining buffer (1% BSA in PBS), and centrifuged (500 ×g, 5 min, 4°C). Five hundred thousand cells were resuspended in 80 μl of staining buffer and 20 μl of diluted antibodies added (5 μg per mL, 1 hour, 4°C). Cells were washed and incubated in 80 μl of staining buffer with 20 μl isotype-APC control (BD cat #555751) or 20 μl anti-Human IgG-APC (BD cat #550931) for 30–45 minutes at 4°C. Cells were washed and fixed with 250 μl of BD Cytofix Buffer (Cat #554655) for 30 minutes at 4°C, and were analyzed on a BD LSRFortessa flow cytometer.

Yu J.S., Liao H.X., Pritchett J., Bowman C., Vivian C., Parks R., Xia S.M., Cooper M., Williams W.B., Bonsignori M., Reed S.G., Chen M., Vandergrift N., Rice C.M, & Haynes B.F. (2017). Development of a Recombinant Yellow Fever Vector Expressing a HIV Clade C Founder Envelope gp120. Journal of virological methods, 249, 85-93.

+ Open protocol

+ Expand

Surface Expression of VRC-A gp145 in 293i Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols

For the surface expression of VRC-A gp145, 293i cells were transfected
with pHV130770 plasmids using ExpiFectamine™ 293 Transfection Kits (Life
Technologies Cat. # A14525) following the manufactures’
protocol. The cells were washed with four volumes of room-temperature
phosphate-buffered saline (DPBS) (Life Technologies Cat # 10010-023),
and centrifuged (500g for 5 minutes). 10⁶ cells were resuspended in
80 µL of staining buffer (1% BSA in DPBS) to which were added 20
µL of diluted antibodies (1 ug per reaction). After incubation (1 hour
at 4°C) with shaking, cells were washed and centrifuged (500 X g). Cells
were incubated with either 20 µL isotype-APC control (BD cat
#555751) or 20 µL anti-Human IgG-APC (BD cat #550931)
for 30–45 minutes at 4°C, protected from light. After washing
and fixation, cells were analyzed by flow cytometer (BD LSRFortessa).

Williams W.B., Liao H.X., Moody M.A., Kepler T.B., Alam S.M., Gao F., Wiehe K., Trama A.M., Jones K., Zhang R., Song H., Marshall D.J., Whitesides J.F., Sawatzki K., Hua A., Liu P., Tay M.Z., Seaton K., Shen X., Foulger A., Lloyd K.E., Parks R., Pollara J., Ferrari G., Yu J.S., Vandergrift N., Montefiori D.C., Sobieszczyk M.E., Hammer S., Karuna S., Gilbert P., Grove D., Grunenberg N., McElrath J., Mascola J.R., Koup R.A., Corey L., Nabel G.J., Morgan C., Churchyard G., Maenza J., Keefer M., Graham B.S., Baden L.R., Tomaras G.D, & Haynes B.F. (2015). Diversion of HIV-1 Vaccine-induced Immunity by gp41-Microbiota Cross-reactive Antibodies. Science (New York, N.Y.), 349(6249), aab1253.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!